£3.0M
The follow-on investment from existing backers will support the expansion of the company's current facilities.
OXGENE
OXGENE develops advanced mammalian cell engineering platforms for the life sciences sector.
£3.0MTotal raised
OXGENE is a life sciences solutions provider specialising in mammalian cell engineering for gene therapy, gene editing and antibody therapeutics. The company builds novel technology platforms that support the discovery, development and manufacture of biological medicines.
Categories
Team
JB
Jo Bath
Chief Operating Officer
SL
Sophie Lutter
Scientific Communications and Marketing Manager
Investors
